SECsense Logo

Lipocine Inc. 8-K Report: Financial Insights & Updates as of February 2025

$LPCN
Form 8-K
Filed on: 2025-02-11
Source
Lipocine Inc. 8-K Report: Financial Insights & Updates as of February 2025

Based on the provided XML section of the financial report, here are the key pieces of information and insights extracted:

  1. Company Information:
  • Entity Name: Lipocine Inc.
  • CIK (Central Index Key): 0001535955
  • IRS Employer Identification Number (EIN): 99-0370688
  • Address: 675 Arapeen Drive, Suite 202, Salt Lake City, UT 84108
  • Contact Number: (801) 994-7383
  1. Filing Information:
  • Filing Type: 8-K (Current Report)
  • Filing Date: February 11, 2025
  • End Date of Reporting Period: February 11, 2025
  1. Stock Information:
  • Common Stock: The company has common stock with a par value of $0.0001 per share.
  • Ticker Symbol: LPCN
  • Exchange: NASDAQ
  1. Financial Measures:
  • Reporting Currency: USD (U.S. Dollar)
  • Unit of Measurement: Shares
  1. Schema Reference:
  • XBRL Schema Reference: The filing references an XBRL schema file named "lpcn-20250211.xsd".

Insights:

  • The filing date coincides with the reporting date, which may indicate that the report contains timely disclosures relevant to current investors or stakeholders.
  • The company is publicly traded on NASDAQ, which suggests it is subject to ongoing regulatory disclosures and compliance with SEC rules.
  • The low par value of the common stock ($0.0001) may imply that the stock is relatively inexpensive per share, which could attract retail investors.
  • The structure of the filing in XBRL (eXtensible Business Reporting Language) indicates that the company is using modern reporting standards that facilitate easier analysis and comparison of financial data.

This information is crucial for investors, analysts, and stakeholders interested in understanding Lipocine Inc.'s financial position and operations as of the specified date.